Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers

The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have already contracted SARS-CoV-2, including in its asymptomatic form. Serological testing in this context would be useful for deploying immune healthcare workers as to limit the risk of viral infection and transmission. Therefore, it is of utmost importance to prove that the serological response entails the production of neutralizing antibodies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID Corona Virus Infection Coronaviridae Infections Coronavirus Infections Infections Nidovirales Infections RNA Virus Infections Virus Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

ECRRM, Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Not previously diagnosed with COVID-19 except for convalescents
Not currently symptomatic with fever or respiratory symptoms (cough, dyspnea)

Exclusion criteria

Patients with fever or respiratory symptoms (cough, dyspnea)
Refusal to give informed consent, or contraindication to venipuncture.

Treatment and study plan

Specific anti-SARS-CoV-2 antibodies

Biological

A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.

All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).

Primary outcomes

Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies

Time frame: 3 Months

Sponsors and collaborators

Lead sponsor

Egyptian Center for Research and Regenerative Medicine

Other Gov

Collaborators

Academy of Scientific Research and Technology, Egypt
Cairo University
National Research Centre, Egypt

Registry information

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: Jun 9, 2020
Registry last updated: Mar 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed